BPC-157

What it is

BPC-157 is a lab-made chain of 15 amino acids, copied from a small piece of a larger protein originally found in human gastric juice. Despite that origin, the 15-amino-acid fragment itself is not something the body is known to make or use as a signal on its own, and researchers have not identified a specific receptor or molecular target that it acts on.

It is sold by injection, nasal spray, and oral capsule, and marketed for injury healing, gut problems, and joint pain. Almost everything known about it comes from laboratory research; the entire documented human record amounts to roughly 80 people across five small studies.

It has never been approved by any regulatory authority anywhere in the world, and there is no completed, published, properly controlled human trial showing that it works for any of the uses it is marketed for.

What people use it for

How it works

Honestly, nobody knows for certain. This isn't a case where the mechanism is understood but untested in people — the basic biology is unresolved too. In laboratory research, giving BPC-157 appears to nudge several general repair systems at once, including nitric oxide signaling and

the growth of new small blood vessels into injured tissue, which in laboratory research helps healing proceed faster.

That same blood-vessel-growth mechanism proposed to explain benefit is also the basis of an unresolved safety question: the pathway involved is active in roughly half of the human cancers studied, and no carcinogenicity study of BPC-157 has ever been performed. No human pharmacokinetic data exists for the routes most people actually use it by — oral, subcutaneous, or nasal. Only rectal, intra-articular, intravesical, and intravenous routes have been studied in humans, and even rectal dosing does not appear to produce meaningful systemic absorption.

What the research actually looked at

Two very different bodies of research exist for BPC-157, and marketing frequently blurs them together: extensive laboratory experiments describing tissue-repair effects, and a genuinely small human record — five studies, roughly 80 people combined, most uncontrolled or unpublished in full.

Of those five human studies, only one was randomized and placebo-controlled, in ulcerative colitis using a rectal route, and it was never published beyond a conference abstract, limiting how much can be evaluated from it. The most frequently cited “human evidence” for joint or injury use is a retrospective chart review of 17 patients with no control group, no blinding, and only subjective outcome measures.

A properly designed, controlled human trial for a musculoskeletal use — a hamstring muscle strain — only began enrolling in 2026, with results not expected before 2028. Until it reports, there is no controlled human evidence for the injury-healing use BPC-157 is most commonly marketed for.

Common misunderstandings

• “It's well studied — there are hundreds of published studies.” There are hundreds of studies, and the overwhelming majority are laboratory research. The entire documented human record is roughly 80 people.
• “It's natural, since it comes from a protein in the stomach.” The 15-amino-acid fragment sold today is a synthetic sequence copied from part of a larger protein; it is not established that the body itself makes or uses this specific fragment as a signal.
• “It's proven to heal tendons and ligaments.” No completed controlled human trial has tested this. The claim rests on laboratory tendon-injury research; the first real human test of a musculoskeletal use began enrolling only in 2026.
• “It has no real side effects because no toxic dose has been found.” No carcinogenicity study has ever been performed on this compound, and the laboratory toxicology that does exist showed liver-enzyme and blood-clotting changes. The absence of a toxic-dose finding reflects that the studies to find one were never done, not that the compound is safe at any dose.

Who it is not for

• Anyone on blood thinners, or with a bleeding or clotting disorder.
• Anyone with liver disease or abnormal liver tests.
• Anyone with active cancer, a cancer history, or an unscreened suspicious finding — the same mechanism proposed for benefit is active in a large share of human cancers, and no carcinogenicity study has ever been performed.
• Pregnant or breastfeeding patients, or anyone trying to conceive.
• Anyone sourcing product from an unverified online vendor rather than a licensed pharmacy.
• Competitive athletes subject to WADA testing.

Competitive athletes: Prohibited at all times, in and out of competition, under WADA's S0 category for substances with no approval anywhere in the world for human therapeutic use. A therapeutic use exemption is not available for an S0 substance, and anti-doping operates on strict liability regardless of a clinician's recommendation — an athlete has been sanctioned for a product containing this compound without ever testing positive for it.

Who makes this, and under what rules

Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:

• A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
• Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
• Sterile preparation to a published standard. USP standards.
• A paper trail. A lot number and beyond-use date on every preparation.

A compounded preparation is not an FDA-approved medicine — but it is the difference between a licensed pharmacy working to a standard and an unregulated website.

Where this stands

Never approved, anywhere, for anything. There is no BPC-157 drug product approved in any country. A 2026 regulatory advisory panel voted narrowly to recommend it for one specific compounding use — inflammatory bowel disease, not injury healing — overriding the reviewing agency's own scientists, who had recommended against it. The vote is advisory only and has not been adopted. The human record is about 80 people, across five small studies. Only one of those studies was randomized and placebo-controlled, and it was never published beyond a conference abstract. The route most people actually use it by — injected under the skin — has zero published human data of any kind. There is a real, unresolved cancer-risk question attached to the same mechanism proposed for its benefit, and no study has ever been done to rule it out.

Clinical detail

A synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV), described as a fragment of a protein originally isolated from human gastric juice; its molecular target has not been identified. The entire documented human record totals approximately 80 people across five small studies, only one of which was randomized and placebo-controlled. No human pharmacokinetic data exists for oral, subcutaneous, nasal, or transdermal administration — the routes most commonly sold to consumers. No carcinogenicity study has ever been performed, and 28-day laboratory toxicology testing found liver-enzyme and blood-clotting changes. A properly controlled human trial for a musculoskeletal indication began enrolling in 2026, with results expected in 2028.

The information on this page is general education. It is not medical advice and it is not a recommendation for any treatment. BPC-157 is not an FDA-approved medicine for the uses described here. A compounded preparation is not an FDA-approved product and has not been reviewed by the FDA for safety, effectiveness or quality. Descriptions of what this is used for reflect how it is commonly used and discussed. They are not claims that it is effective for any purpose. Any prescription follows an individual evaluation by a licensed provider and is issued only where that provider judges it clinically appropriate. A prescription is never guaranteed.